FDA Approves Telix’s Brain Cancer Imaging Drug Pixclara
Telix Pharmaceuticals has received FDA approval for Pixclara®, a novel radioactive diagnostic PET imaging drug indicated to differentiate recurrent or progressive glioma from treatment-related changes in both adult and pediatric patients. This first FDA-approved FET-PET imaging agent for glioma offers physicians enhanced diagnostic precision and tr…